Janssen filed a lawsuit against Amgen, claiming the latter infringed on the former’s patents when creating its ustekinumab biosimilar, and Express Scripts announced that it would add adalimumab biosimilars to formulary.
Johnson & Johnson’s Janssen unit filed a lawsuit against Amgen, claiming the latter infringed on the former’s patents when creating its ustekinumab biosimilar, and Express Scripts announced that it would add adalimumab biosimilars to formulary.
Janssen Sues Amgen Over Ustekinumab Biosimilar
Janssen, a division of Johnson & Johnson (J&J), sued Amgen over its ustekinumab biosimilar referencing Stelara, claiming that Amgen’s intention to market the drug for rheumatic and gastrointestinal conditions infringes 2 of Janssen’s patents for the originator, according to a report from Reuters.
Stelara accumulated $9.1 billion in 2021, which represented about 18% of Janssen’s total annual revenue ($52 billion). Sales for the first 9 months of 2022 generated $7.3 billion for the company, up 7.9% from the same timeframe the previous year. Ustekinumab is used to treat Crohn disease, psoriasis, psoriatic arthritis, and ulcerative colitis.
J&J informed the court that Amgen’s filing indicates that the FDA will approve its biosimilar in the second for third quarter of 2023. Amgen is planning to launch the drug as early as next May.
The court filing could signal a pay-for-delay scheme in the ustekinumab space, a common move in the pharmaceutical industry, where a biosimilar manufacturer may pay to settle a patent infringement case in exchange for biosimilar launch postponement. This is the reasoning behind why adalimumab biosimilars are not allowed to enter the US market until 2023 despite being on the European and Canadian markets for several years.
Express Scripts to Cover Adalimumab Biosimilars
Following in the footsteps of OptumRx, Cigna’s pharmacy benefit manager (PBM) Express Scripts announced that it will add multiple adalimumab biosimilars to it formulary list at parity with the originator (Humira), according to Forbes.
Humira generates over $20 billion annually for drugmaker AbbVie, and come 2023, up to 10 adalimumab biosimilars will enter the US market: 1 in January followed by at least 7 in July. For years, stakeholders have wondered whether payers and PBMs were going to enact policies that would cover adalimumab biosimilars and how that coverage would compare with the originator.
“This decision helps us achieve lower costs for patients and plans while giving patients and providers choice and flexibility as additional biosimilars come to market…. Lack of competition allows sky-high prescription drug prices. We can generate more competition in the inflammatory drug class by adding biosimilars to our largest formularies in the coming months and…lower the costs of medications for the millions of people we serve,” said Harold Carter, chief pharma trade relations officer for Express Scripts.
Express Scripts did not disclose how many or which adalimumab biosimilars will be added to the formulary.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.